The Qool Therapeutics Team

Our management team, board of directors and clinical advisors are a select group of physicians, specialists and experts in the field of therapeutic hypothermia and medical devices.

 

The Qool Therapeutics Team

Our management team, board of directors and clinical advisors are a select group of physicians, specialists and experts in the field of therapeutic hypothermia and medical devices.

Management Team

 

Beverly Huss, M.S. – President and CEO

Beverly Huss joined Qool Therapeutics as President and CEO in September 2013.  Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity.  Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years.

Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company.

Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular and obesity medical device areas. Beverly serves on the board of Surefire Medical, Ciel Medical, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. Ms. Huss was the recipient of the 2013 University Of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

Amir Belson, M.D. – Founder and Chief Technology Officer

Amir is the founder of Qool Therapeutics and is a serial entrepreneur.  Prior to founding the company, Amir conceived of and started ZipLine Medical, was the founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures that was later acquired by Intuitive Surgical in 2009. He is also the founder of Vascular Pathways, a company that developed an FDA cleared vascular intervention technology that has been chosen as one of the 10 best inventions of 2009 by Popular Science magazine and was acquired by C.R Bard in 2015. In addition, Amir founded Radiaction, a radiation protection medical device company and VasoStitch, which develops large vessel access and closure technology.

Amir graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford. He also served several years as a flight surgeon in Israel’s air force rescue unit before moving to the US for a three year Pediatric Nephrology fellowship at Stanford University Medical Center. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.

Mike Horzewski – Senior Vice President of Research and Development and Operations

Mike Horzewski joined Qool Therapeutics as Senior Vice President of R&D and Operations in May 2017. Previously, he served as Chief Operating Officer of VytronUS, developing ultrasound imaging and ablation devices for atrial fibrillation and other areas of the body, where he led the team from early design stages through successful clinical trials.

Prior to VytronUS, Mike started Timi3 Systems and served as Vice President of R&D and Manufacturing. Initially focused on ultrasound to treat heart attacks, he led a restart of the company as President and CEO and successfully enabled licensing of the technology.  Mike was a co-founder and Director of Engineering at Danforth Biomedical, a medical device consulting firm, which was acquired by ACT Medical. Before joining Danforth, Mike worked for Advanced Cardiovascular Systems (Guidant Corporation) as a Project Engineer.  Working with Paul Yock, M.D., Mike developed the industry’s first Rapid Exchange catheter.

Mike earned a B.S. in Biomedical Engineering from the University of Southern California. He holds 46 U.S. patents and has several publications. He has served as an expert witness in medical device patent litigation and on the University of Southern California School of Biomedical Engineering advisory board.

Kim Tompkins, R.N. M.B.A. – Vice President of Regulatory, Quality and Clinical Affairs

Kim Tompkins joined Qool Therapeutics as VP of Regulatory, Quality and Clinical Affairs in February 2018. Previously, Kim was VP of Regulatory and Clinical at HMicro, Inc. a company that developed a proprietary IC with medical applications in the digital health market. Prior to that, Kim held executive level positions at Bioness, Inc., VasoNova, Inc. (acquired by Teleflex), Ardian, Inc. (acquired by Medtronic), and CryoVascular Systems, Inc. (acquired by Boston Scientific) among others primarily in the cardiovascular, peripheral vascular, orthopedic and aesthetic medical device markets.

Kim earned an MBA in Business Administration from Indiana University (IPFW), a BS in Computer Technology and an AAS in Nursing Technology from Purdue University (IPFW). She holds RN licenses to practice in Indiana and California, has a patent pending and has co-authored several publications.

Beverly Huss, M.S. – President and CEO

Beverly Huss joined Qool Therapeutics as President and CEO in September 2013.  Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity.  Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years.

Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company.

Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular and obesity medical device areas. Beverly serves on the board of Surefire Medical, Ciel Medical, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. Ms. Huss was the recipient of the 2013 University Of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.

Amir Belson, M.D. – Founder and Chief Technology Officer

Amir is the founder of Qool Therapeutics and is a serial entrepreneur.  Prior to founding the company, Amir conceived of and started ZipLine Medical, was the founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures that was later acquired by Intuitive Surgical in 2009. He is also the founder of Vascular Pathways, a company that developed an FDA cleared vascular intervention technology that has been chosen as one of the 10 best inventions of 2009 by Popular Science magazine and was acquired by C.R Bard in 2015. In addition, Amir founded Radiaction, a radiation protection medical device company and VasoStitch, which develops large vessel access and closure technology.

Amir graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford. He also served several years as a flight surgeon in Israel’s air force rescue unit before moving to the US for a three year Pediatric Nephrology fellowship at Stanford University Medical Center. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.

Mike Horzewski – Senior Vice President of Research and Development and Operations

Mike Horzewski joined Qool Therapeutics as Senior Vice President of R&D and Operations in May 2017. Previously, he served as Chief Operating Officer of VytronUS, developing ultrasound imaging and ablation devices for atrial fibrillation and other areas of the body, where he led the team from early design stages through successful clinical trials.

Prior to VytronUS, Mike started Timi3 Systems and served as Vice President of R&D and Manufacturing. Initially focused on ultrasound to treat heart attacks, he led a restart of the company as President and CEO and successfully enabled licensing of the technology.  Mike was a co-founder and Director of Engineering at Danforth Biomedical, a medical device consulting firm, which was acquired by ACT Medical. Before joining Danforth, Mike worked for Advanced Cardiovascular Systems (Guidant Corporation) as a Project Engineer.  Working with Paul Yock, M.D., Mike developed the industry’s first Rapid Exchange catheter.

Mike earned a B.S. in Biomedical Engineering from the University of Southern California. He holds 46 U.S. patents and has several publications. He has served as an expert witness in medical device patent litigation and on the University of Southern California School of Biomedical Engineering advisory board.

Kim Tompkins, R.N. M.B.A. – Vice President of Regulatory, Quality and Clinical Affairs

Kim Tompkins joined Qool Therapeutics as VP of Regulatory, Quality and Clinical Affairs in February 2018. Previously, Kim was VP of Regulatory and Clinical at HMicro, Inc. a company that developed a proprietary IC with medical applications in the digital health market. Prior to that, Kim held executive level positions at Bioness, Inc., VasoNova, Inc. (acquired by Teleflex), Ardian, Inc. (acquired by Medtronic), and CryoVascular Systems, Inc. (acquired by Boston Scientific) among others primarily in the cardiovascular, peripheral vascular, orthopedic and aesthetic medical device markets.

Kim earned an MBA in Business Administration from Indiana University (IPFW), a BS in Computer Technology and an AAS in Nursing Technology from Purdue University (IPFW). She holds RN licenses to practice in Indiana and California, has a patent pending and has co-authored several publications.

Board of Directors

 

Beverly Huss, M.S.

President and CEO

Amir Belson, M.D.

Founder and Chief Technology Officer

Ronald Dieck

Ronald Dieck was a founder, President and CEO of Tenaxis Medical, recently acquired by The Medicines Company.   In addition to Tenaxis Medical, he was a founder of PneumRx, Magic Venture Capital, Spinal Concepts and founder, President and CEO of Micro Interventional Systems.  He has held executive positions at American Hospital Supply, Baxter Healthcare, Wright Medical and American Medical Electronics.

Mr. Dieck has additionally served as a Director with Interface Catheter Solutions and the Asian American Institute for Research and Education.  He has extensive experience in general management, research and development, marketing, manufacturing and private equity financing.

Mr. Dieck holds a B.A. in chemistry from Ripon College and a Ph.D. in Chemistry from Arizona State University.  He is the inventor of over fifty United States Patents and has authored over forty technical papers.

Frederic Moll, M.D.

Frederic H. Moll, M.D. serves as Chairman and Chief Executive Office of Auris Surgical Robotics, a private company located in San Carlos, California. Dr. Moll is a distinguished medical device entrepreneur and has more than 20 years of medical device and high technology experience.

In 1995, Dr. Moll founded Intuitive Surgical, Inc. (Nasdaq:ISRG), serving as the company’s first CEO. Prior to Intuitive Surgical, Dr. Moll co-founded Origin Medsystems, Inc. which was acquired by Eli Lilly in 1992 and later became an operating company within the Guidant Corporation. Before co-founding Origin Medsystems, Dr. Moll founded Endotherapeutics Corporation, a pioneering company in laparoscopic surgical technology. Endotherapeutics was acquired by U.S. Surgical in 1992. Dr. Moll also serves on the Boards of several Silicon Valley healthcare companies.

Dr. Moll is a distinguished speaker and lecturer and is the author of numerous scientific articles. Dr. Moll received an M.D. from the University of Washington’s School of Medicine, an M.S. degree in Management from Stanford University’s Sloan Program, and a B.A. degree from the University of California at Berkeley.

Zhu Jianqing

Mr. Zhu Jianqing joined the Qool Therapeutics Board of Directors in November 2017. Prior to that, Mr. Zhu served as a corporate executive in China’s domestic real estate industry and as a deputy general manager and then the general manager of Jiangsu Zhongji Properties Co., Ltd. since 2006.

In 2016, with a view to serve the development of the medical technology industry, he became a deputy general manager of Beijing Join Medical Technology Co., Ltd.

Mr. Zhu graduated in December 2005 with a master’s degree in finance from Victoria University of Wellington. After graduation, he returned to his motherland to engage in corporate operations in the real estate sector. In 2012, he completed his EMBA re-education at Nanjing University and gained extensive experience in foreign investment and business management.

Renfu Zhou

Renfu Zhou currently holds the positions of managing director at Jingwei Pharmaceutical Technology Group Co., Ltd. and Beijing Join Medical Technology Co., Ltd. His 20 years of engagement in the pharmaceutical industry, working in the development, production, sales and logistics of drugs and medical devices, has provided him with rich experience in marketing and corporate management.

Mr. Zhou started the first private retail chain pharmacy in China, Jinwei Pharmacy, in 1999. He followed this with yaofang.cn, China’s first online pharmacy. By utilizing the combination of online and offline platforms he was the first to create the DTC (direct-to-consumer) pharmaceutical marketing model in China.

His 18-year army career has built in his character determination, strength and persistence. He obtained the title of “pharmacist-in-charge” after graduation from a medical college with a major in pharmacy.

 

Beverly Huss, M.S.

President and CEO

Amir Belson, M.D.

Founder and Chief Technology Officer

Ronald Dieck

Ronald Dieck was a founder, President and CEO of Tenaxis Medical, recently acquired by The Medicines Company.   In addition to Tenaxis Medical, he was a founder of PneumRx, Magic Venture Capital, Spinal Concepts and founder, President and CEO of Micro Interventional Systems.  He has held executive positions at American Hospital Supply, Baxter Healthcare, Wright Medical and American Medical Electronics.

Mr. Dieck has additionally served as a Director with Interface Catheter Solutions and the Asian American Institute for Research and Education.  He has extensive experience in general management, research and development, marketing, manufacturing and private equity financing.

Mr. Dieck holds a B.A. in chemistry from Ripon College and a Ph.D. in Chemistry from Arizona State University.  He is the inventor of over fifty United States Patents and has authored over forty technical papers.

Frederic Moll, M.D.

Frederic H. Moll, M.D. serves as Chairman and Chief Executive Office of Auris Surgical Robotics, a private company located in San Carlos, California. Dr. Moll is a distinguished medical device entrepreneur and has more than 20 years of medical device and high technology experience.

In 1995, Dr. Moll founded Intuitive Surgical, Inc. (Nasdaq:ISRG), serving as the company’s first CEO. Prior to Intuitive Surgical, Dr. Moll co-founded Origin Medsystems, Inc. which was acquired by Eli Lilly in 1992 and later became an operating company within the Guidant Corporation. Before co-founding Origin Medsystems, Dr. Moll founded Endotherapeutics Corporation, a pioneering company in laparoscopic surgical technology. Endotherapeutics was acquired by U.S. Surgical in 1992. Dr. Moll also serves on the Boards of several Silicon Valley healthcare companies.

Dr. Moll is a distinguished speaker and lecturer and is the author of numerous scientific articles. Dr. Moll received an M.D. from the University of Washington’s School of Medicine, an M.S. degree in Management from Stanford University’s Sloan Program, and a B.A. degree from the University of California at Berkeley.

Zhu Jianqing

Mr. Zhu Jianqing joined the Qool Therapeutics Board of Directors in November 2017. Prior to that, Mr. Zhu served as a corporate executive in China’s domestic real estate industry and as a deputy general manager and then the general manager of Jiangsu Zhongji Properties Co., Ltd. since 2006.

In 2016, with a view to serve the development of the medical technology industry, he became a deputy general manager of Beijing Join Medical Technology Co., Ltd.

Mr. Zhu graduated in December 2005 with a master’s degree in finance from Victoria University of Wellington. After graduation, he returned to his motherland to engage in corporate operations in the real estate sector. In 2012, he completed his EMBA re-education at Nanjing University and gained extensive experience in foreign investment and business management.

Renfu Zhou

Renfu Zhou currently holds the positions of managing director at Jingwei Pharmaceutical Technology Group Co., Ltd. and Beijing Join Medical Technology Co., Ltd. His 20 years of engagement in the pharmaceutical industry, working in the development, production, sales and logistics of drugs and medical devices, has provided him with rich experience in marketing and corporate management.

Mr. Zhou started the first private retail chain pharmacy in China, Jinwei Pharmacy, in 1999. He followed this with yaofang.cn, China’s first online pharmacy. By utilizing the combination of online and offline platforms he was the first to create the DTC (direct-to-consumer) pharmaceutical marketing model in China.

His 18-year army career has built in his character determination, strength and persistence. He obtained the title of “pharmacist-in-charge” after graduation from a medical college with a major in pharmacy.

Clinical Advisors

 

Michael Dae, M.D., MBA

UCSF Professor of Radiology and Medicine
Former Chief Medical Officer, Radiant Medical

W. Dalton Dietrich, Ph.D.

University of Miami
Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology & Anatomy

Michael F. Dillingham, M.D.

SOAR  Sports, Orthopedic Surgery and Rehabilitation Medicine Associates
San Francisco Giants, Team Physician

Elazer Edelman, M.D., Ph.D.

MIT, Professor of Health Sciences and Technology, Professor of Medicine
Harvard Medical School Director, Director Harvard-MIT Biomedical Engineering Center

Carmelo Graffagnino, M.D.

Duke University
Professor of Neurology, Division Chief, Neurocritical Care

Jim Heslin, JD

Patent counsel
Wilson, Sonsini, Goodrich and Rosati

Thomas Krummel, M.D.

Stanford University
Former Surgeon in Chief, Co-Director, Biodesign Program

Steve  Ruoss, M.D.

Stanford University
Co-Chief, Pulmonary and Critical Care Medicine

Gary Steinberg, M.D., Ph.D.

Stanford University
Professor of Neurosurgery and  Neurosciences, Chairman, Dept. of Neurosurgery, Co-Director, Stroke Center

Gregg Stone, M.D.

Columbia University
Director of Cardiovascular Research and Education Medical Center / New York-Presbyterian Hospital

Kristine Tatsutani, Ph.D.

Serial entrepreneur, cryobiologist, medical device executive venture backed and Fortune 500 companies; former Chief Science Officer Zeltiq

Renu Virmani, M.D.

Georgetown University
Founder and Director of CVPath Institute, Clinical Professor, Department of Pathology

Paul Yock, M.D.

Stanford University, Professor of Medicine
Founder, Director, Biodesign Program

Michael Dae, M.D., MBA

UCSF Professor of Radiology and Medicine
Former Chief Medical Officer, Radiant Medical

W. Dalton Dietrich, Ph.D.

University of Miami
Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology & Anatomy

Michael F. Dillingham, M.D.

SOAR  Sports, Orthopedic Surgery and Rehabilitation Medicine Associates
San Francisco Giants, Team Physician

Elazer Edelman, M.D., Ph.D.

MIT, Professor of Health Sciences and Technology, Professor of Medicine
Harvard Medical School Director, Director Harvard-MIT Biomedical Engineering Center

Carmelo Graffagnino, M.D.

Duke University
Professor of Neurology, Division Chief, Neurocritical Care

Jim Heslin, JD

Patent counsel
Wilson, Sonsini, Goodrich and Rosati

Thomas Krummel, M.D.

Stanford University
Former Surgeon in Chief, Co-Director, Biodesign Program

Steve  Ruoss, M.D.

Stanford University
Co-Chief, Pulmonary and Critical Care Medicine

Gary Steinberg, M.D., Ph.D.

Stanford University
Professor of Neurosurgery and  Neurosciences, Chairman, Dept. of Neurosurgery, Co-Director, Stroke Center

Gregg Stone, M.D.

Columbia University
Director of Cardiovascular Research and Education Medical Center / New York-Presbyterian Hospital

Kristine Tatsutani, Ph.D.

Serial entrepreneur, cryobiologist, medical device executive venture backed and Fortune 500 companies; former Chief Science Officer Zeltiq

Renu Virmani, M.D.

Georgetown University
Founder and Director of CVPath Institute, Clinical Professor, Department of Pathology

Paul Yock, M.D.

Stanford University, Professor of Medicine
Founder, Director, Biodesign Program